Ex dividend NOK 4.00 today

New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement

New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting

Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China

Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC

Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.

New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia

Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance

Bladder Cancer technology: New KARL STORZ Blue Light Cystoscopy system featured during E-Masterclass in Urology